Dew, I want to revisit the 184/320 DDI study again briefly after thinking about this some more as I don't recall a lot of discussion in the prior threads about the 400mg QD dose of 320 that was used in the DDI study. Given the potency of the 100mg QD dose of 320 in the 3-day PoC study, which probably showed that a 100mg QD dose of 320 is plenty potent enough (I believe 3.1 log drop after 3 days) as part of an HCV DAA combo, do you see any chance that IDIX can convince the FDA of allowing it to move forward in testing 320, either alone or even with 184, at a much smaller dose like 100mg QD? Presumably fleshing out whether there is a signal from a much lower dose of 320 in combo with 184 will be a focus of the animal toxicology studies.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.